Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

Radiology and Oncology

Jelercic Stasa¹  Stanic Karmen¹  But-Hadzic Jasna¹  Vrankar Martina¹  Vodusek Ana Lina¹  Ciric Eva¹ 

[1] Institute of Oncology Ljubljana, Department of Radiotherapy, Ljubljana, Slovenia;

关键词: non-small cell lung cancer;    stage iii;    chemoradiotherapy;    durvalumab;   

DOI  :  10.2478/raon-2021-0044

来源: DOAJ

【 摘 要 】

Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.

【 授权许可】

Unknown